Daily Anesthesiology Research Analysis
Three studies advance anesthesiology and perioperative care: (1) a Science Advances paper maps a conformation-specific propofol binding pocket in the HCN1 voltage-sensor domain, explaining voltage-dependent inhibition and enabling rational modulator design; (2) a non-inferiority RCT in cardiac surgery shows remimazolam was not non-inferior to etomidate for post-induction hypotension; (3) an open-source pipeline (pyAKI) accurately automates KDIGO AKI classification on ICU time-series, standardizi
Summary
Three studies advance anesthesiology and perioperative care: (1) a Science Advances paper maps a conformation-specific propofol binding pocket in the HCN1 voltage-sensor domain, explaining voltage-dependent inhibition and enabling rational modulator design; (2) a non-inferiority RCT in cardiac surgery shows remimazolam was not non-inferior to etomidate for post-induction hypotension; (3) an open-source pipeline (pyAKI) accurately automates KDIGO AKI classification on ICU time-series, standardizing research workflows.
Research Themes
- Molecular pharmacology of anesthetics and ion channel gating
- Hemodynamic safety of induction agents in high-risk cardiac anesthesia
- Open-source informatics for ICU phenotyping and AKI classification
Selected Articles
1. A propofol binding site in the voltage sensor domain mediates inhibition of HCN1 channel activity.
Using photoaffinity labeling, mass spectrometry, and molecular dynamics, the authors identify a resting-state binding pocket for propofol in the HCN1 voltage sensor (S3–S4). Mutagenesis within this pocket abrogates propofol’s voltage-dependent inhibition, revealing a conformation-specific site that explains HCN modulation and guides design of selective HCN modulators.
Impact: This work pinpoints a conformation-specific anesthetic binding site on HCN1, resolving a longstanding mechanistic question and enabling rational development of analgesic/anesthetic modulators with improved specificity.
Clinical Implications: While preclinical, the identified binding pocket explains propofol’s HCN-mediated effects (e.g., analgesia, bradycardia risk) and could inform next-generation agents that modulate HCN gating without off-target effects.
Key Findings
- Photoaffinity labeling identified a propofol binding site in the HCN1 voltage sensor domain.
- MS and MD simulations localized a resting-state pocket formed by extracellular S3–S4 residues.
- Mutating pocket residues abolished voltage-dependent inhibition of HCN1 by propofol.
Methodological Strengths
- Triangulation of photoaffinity labeling, mass spectrometry, and MD simulations
- Functional validation via site-directed mutagenesis and electrophysiology
Limitations
- Findings focused on HCN1 isoform; generalizability to other HCN isoforms not directly tested
- No high-resolution structural (e.g., cryo-EM) complex of propofol–HCN1 presented
Future Directions: Solve high-resolution structures of propofol-bound HCN states; test isoform-specificity and in vivo relevance; leverage the pocket to design selective HCN modulators for analgesia and arrhythmia modulation.
Hyperpolarization-activated and cyclic nucleotide-gated (HCN) ion channels are members of the cyclic nucleotide-binding family and are crucial for regulating cellular automaticity in many excitable cells. HCN channel activation contributes to pain perception, and propofol, a widely used anesthetic, acts as an analgesic by inhibiting the voltage-dependent activity of HCN channels. However, the molecular determinants of propofol action on HCN channels remain unknown. Here, we use a propofol-analog photoaffinity labeling reagent to identify propofol binding sites in the human HCN1 isoform. Mass spectrometry analyses combined with molecular dynamics simulations show that a binding pocket is formed by extracellularly facing residues in the S3 and S4 transmembrane segments in the resting voltage-sensor conformation. Mutations of residues within the putative binding pocket mitigate or eliminate voltage-dependent modulation of HCN1 currents by propofol. Together, these findings reveal a conformation-specific propofol binding site that underlies voltage-dependent inhibition of HCN currents and provides a framework for identifying highly specific modulators of HCN channel gating.
2. pyAKI-An open source solution to automated acute kidney injury classification.
pyAKI standardizes KDIGO-based AKI classification from ICU time-series using a reproducible data model and dual-input algorithm (serum creatinine and urine output). Validated against expert annotations on MIMIC-IV, it achieved perfect accuracy across categories, offering the first open-source, end-to-end solution for consistent AKI labeling.
Impact: By eliminating inconsistent edge-case interpretations and offering code/data transparency, pyAKI can harmonize AKI endpoints across studies, boosting reproducibility and enabling multicenter perioperative/ICU research.
Clinical Implications: While a research tool, pyAKI can underpin robust decision-support, audit, and quality-improvement pipelines in perioperative and critical care settings where AKI is common.
Key Findings
- First open-source, standardized pipeline implementing KDIGO AKI criteria on ICU time-series.
- Validated on MIMIC-IV subset with accuracy of 1.0 versus expert annotations across all categories.
- Implements a reproducible data model using serum creatinine and urine output.
Methodological Strengths
- Open-source code with standardized data model enabling reproducibility
- External validation against clinician annotations with head-to-head accuracy assessment
Limitations
- Validation on a subset of a single database (MIMIC-IV) may limit generalizability without multicenter testing
- Clinical impact on outcomes not assessed; tool performance in noisy real-time streams unproven
Future Directions: Benchmark across diverse EHRs and institutions, integrate into real-time clinical decision-support, and extend to AKI staging/trajectory prediction using probabilistic or ML approaches.
OBJECTIVE: Acute kidney injury (AKI) is a frequent complication in critically ill patients, affecting up to 50% of patients in the intensive care units. The lack of standardized and open-source tools for applying the Kidney Disease Improving Global Outcomes (KDIGO) criteria to time series, requires researchers to implement classification algorithms of their own which is resource intensive and might impact study quality by introducing different interpretations of edge cases. This project introduces pyAKI, an open-source pipeline addressing this gap by providing a comprehensive solution for consistent KDIGO criteria implementation. MATERIALS AND METHODS: The pyAKI pipeline was developed and validated using a subset of the Medical Information Mart for Intensive Care (MIMIC)-IV database, a commonly used database in critical care research. We constructed a standardized data model in order to ensure reproducibility. PyAKI implements the Kidney Disease: Improving Global Outcomes (KDIGO) guideline on AKI diagnosis. After implementation of the diagnostic algorithm, using both serum creatinine and urinary output data, pyAKI was tested on a subset of patients and diagnostic accuracy was compared in a comparative analysis against annotations by physicians. RESULTS: Validation against expert annotations demonstrated pyAKI's robust performance in implementing KDIGO criteria. Comparative analysis revealed its ability to surpass the quality of human labels with an accuracy of 1.0 in all categories. DISCUSSION: The pyAKI pipeline is the first open-source solution for implementing KDIGO criteria in time series data. It provides a standardized data model and a comprehensive solution for consistent AKI classification in research applications for clinicians and data scientists working with AKI data. The pipeline's high accuracy make it a valuable tool for clinical research and decision support systems. CONCLUSION: This work introduces pyAKI as an open-source solution for implementing the KDIGO criteria for AKI diagnosis using time series data with high accuracy and performance.
3. Hypotension after induction of anesthesia with remimazolam or etomidate: a non-inferiority randomized controlled trial in patients undergoing coronary artery bypass grafting.
In CABG patients, post-induction hypotension occurred in 50.7% with remimazolam vs 34.2% with etomidate; the 16.5% difference exceeded the 12% non-inferiority margin. Vasopressor use was similar, indicating remimazolam did not meet non-inferiority for hemodynamic stability versus etomidate under the tested regimen.
Impact: Provides high-quality, negative RCT evidence in a high-risk population, informing induction agent selection and protocol design in cardiac anesthesia.
Clinical Implications: For hemodynamically fragile CABG patients, etomidate may remain preferable for minimizing early hypotension; if choosing remimazolam, consider dose/infusion optimization, vigilant monitoring, and readiness for vasopressors.
Key Findings
- Post-induction hypotension: 50.7% (remimazolam) vs 34.2% (etomidate); difference 16.5% (95% CI 3.0–32.6), exceeding 12% non-inferiority margin.
- BIS-guided induction with remimazolam (6 mg/kg/h) did not achieve non-inferiority to etomidate (0.3 mg/kg).
- Vasopressor requirements were similar between groups.
Methodological Strengths
- Randomized non-inferiority design with prespecified margin and BIS-guided depth control
- Clinical relevance in a homogeneous high-risk CABG population
Limitations
- Single-center trial with modest sample size; generalizability may be limited
- Only one remimazolam dosing strategy tested; optimal regimen may differ
Future Directions: Compare alternative remimazolam dosing/infusion strategies versus etomidate across cardiac and non-cardiac high-risk cohorts; assess composite outcomes (hypotension burden, vasopressor dose, organ injury).
BACKGROUND: Remimazolam is a novel ultra-short-acting benzodiazepine known for its hemodynamic stability over propofol. However, its hemodynamic effects compared to those of etomidate are not well established. This study aimed to determine whether the use of remimazolam is non-inferior to etomidate with regard to the occurrence of post-induction hypotension in patients undergoing coronary artery bypass grafting. METHODS: Patients were randomly assigned to either the remimazolam group (6 mg/kg/h) or the etomidate group (0.3 mg/kg) for induction of anesthesia. Anesthetic depth was adjusted based on the bispectral index. Primary outcome was the incidence of post-induction hypotension, defined as a mean arterial pressure less than 65 mmHg within 15 min after endotracheal intubation, with a non-inferiority margin of 12%. RESULTS: A total of 144 patients were finally analyzed. Incidence of post-induction hypotension was 36/71 (50.7%) in the remimazolam group and 25/73 (34.2%) in the etomidate group, with a rate difference of 16.5% (95% CI [3.0-32.6]) between the two groups that was beyond the prespecified non-inferiority margin of 12.0%. The number of patients who needed vasopressors was similar in the two groups. CONCLUSIONS: In this non-inferiority trial, remimazolam failed to show non-inferiority to etomidate in terms of post-induction hypotension when used as an induction drug for general anesthesia in patients undergoing coronary artery bypass grafting. However, different doses or infusion techniques of remimazolam should be compared with etomidate in various patient groups to fully assess its hemodynamic non-inferiority during induction of anesthesia.